- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis

- Ascendis to initiate multiple programs in metabolic and cardiovascular diseases, including obesity

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that it will regain the exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. This follows termination of the collaboration agreement between Ascendis and Novo Nordisk A/S announced in November 2024. Under the terms of the agreement, following termination all licenses granted to Novo Nordisk in metabolic and cardiovascular diseases, including for once-monthly TransCon Semaglutide, will revert to Ascendis, and neither party has any continuing financial obligations to the other.

Upon effective termination and reversion of rights, Ascendis plans to initiate multiple programs in both rare and large metabolic and cardiovascular indications, where it believes it can establish best-in-class therapies. These new programs include advancing once-monthly TransCon Semaglutide, an investigational long-acting prodrug of the GLP-1 receptor agonist semaglutide, as a potential treatment for obesity and type 2 diabetes.